Kaposis sarcoma in an HIV-positive person successfully treated with paclitaxel

Indian Journal of Dermatology, Venereology and Leprology

Volumn 75, Issue 3, 2009, Pages 290-292

  Dongre, Atul ^a,b   Montaldo, Chiara ^a  

^a Medicines Sans Frontieres Belgique (MSF B)   (India)

^b MSF Clinic   (India)

Author keywords

AIDS; HAART; HIV; Kaposi s sarcoma; Paclitaxel

Indexed keywords

EFAVIRENZ; LAMIVUDINE; PACLITAXEL; STAVUDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; SKIN BIOPSY; TREATMENT RESPONSE;

ADULT; HIV INFECTIONS; HUMANS; MALE; PACLITAXEL; SARCOMA, KAPOSI;

EID: 67249148909     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.51254     Document Type: Article

References (12)

1. Wahman A, Melnick SL, Rhame FS, Potter JD. The epidemiology of classic, African, and immunosuppressed Kaposi's sarcoma. Epidemiol Rev 1991;13:178-99.
2. Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi's sarcoma in Northeastern Nigeria. Singapore Med J 2006;47:1069-74.
3. Chachoua A, Krigel R, Lafleur F, Ostreicher R, Speer M, Laubenstein L, et al. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. J Clin Oncol 1989;7:774-80.
4. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification, AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997;15:3085-92.
5. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado R F. AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis 2008;18:189-94.
6. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitor or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17:17-22.
7. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
8. Brambilla L, Romanelli A, Bellinvia M, Ferrucci S, Vinci M, Boneschi V, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: Experience in 17 cases. Br J Dermatol 2008;158:1339-44.
9. Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95:147-54.
10. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-21.
11. Hsu CH, Chen MY, Cheng AL. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel. Anticancer Res 2000;20:1159-61.
12. Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-83.